All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
81 - 90 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Infographic
An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Author(s): Capdevila et al.
An open-label, Phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Author(s): Laban et al.
Obrixtamig (BI 764532) in patients with relapsed/refractory DLL3-high expressing epNEC: trial in progress of the dose expansion part of the Phase II DAREON®-5 trial
Author(s): Pavel et al.
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
Zongertinib as first-line therapy in people living with HER2-mutant lung cancer: Beamion™ LUNG-1
Author(s): Popat et al.
DAREON®-9, a Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small cell lung cancer: updated results
Author(s): Wermke et al.
Zongertinib in People with Previously Treated HER2-Mutant Lung Cancer and Brain Tumors at Baseline: Beamion™ LUNG-1
Author(s): Ruiter et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, PD-L1-positive HNSCC
Author(s): Shroff et al.
Systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: Initial results from a Phase Ia study
Author(s): Harrington et al.
Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumors: updated data
Author(s): Wermke et al.